BioRegnum: The fog of M&A. What constitutes a legit buyout ‘scoop’ these days?
The view from Endpoints
The competition between Reuters, Bloomberg and the Wall Street Journal to break the next big M&A story keeps lowering the bar on what qualifies as a significant new move in the bidding process.
Reuters is off and running with one of the latest scoops, reporting that Merck has joined a group of at least five companies that have “submitted indications of interest” for Medivation. There’s no clear idea just what that means, or where Merck $MRK might fit in the auction after Sanofi went public with its last offer. But we’re all talking about it.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.